Top

Published in:

01-12-2018 | Original Research

Genetic Counselors’ Perspectives About Cell-Free DNA: Experiences, Challenges, and Expectations for Obstetricians

Authors: Patricia K. Agatisa, Mary Beth Mercer, Marissa Coleridge, Ruth M. Farrell

Published in: Journal of Genetic Counseling | Issue 6/2018

Abstract

The expansion of cell-free fetal DNA (cfDNA) screening for a larger and diverse set of genetic variants, in addition for use among the low-risk obstetric population, presents important clinical challenges for all healthcare providers involved in the delivery of prenatal care. It is unclear how to leverage the different members of the healthcare team to respond to these challenges. We conducted interviews with 25 prenatal genetic counselors to understand their experience with the continued expansion of cfDNA screening. Participants supported the use of cfDNA screening for the common autosomal aneuploidies, but noted some reservations for its use to identify fetal sex and microdeletions. Participants reported several barriers to ensuring that patients have the information and support to make informed decisions about using cfDNA to screen for these different conditions. This was seen as a dual-sided problem, and necessitated additional education interventions that addressed patients seeking cfDNA screening, and obstetricians who introduce the concepts of genetic risk and cfDNA to patients. In addition, participants noted that they have a professional responsibility to educate obstetricians about cfDNA so they can be prepared to be gatekeepers of counseling and education about this screening option for use among the general obstetric population.

Agarwal, A., Sayres, L. C., Cho, M. K., Cook-Deegan, R., & Chandrasekharan, S. (2013). Commercial landscape of noninvasive prenatal testing in the United States. Prenatal Diagnosis, 33, 521–531.CrossRef

Alexander, E., Kelly, S., & Kerzin-Storrar, L. (2015). Non-invasive prenatal testing: UK genetic counselors’ experiences and perspectives. Journal of Genetic Counseling, 24, 300–311.CrossRef

Allyse, M. A., Sayres, L. C., Havard, M., King, J. S., Greely, H. T., Hudgins, L., Taylor, J., Norton, M. E., Cho, M. K., Magnus, D., & Ormond, K. E. (2013). Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testing. Prenatal Diagnosis, 33, 656–661.CrossRef

American College of Obstetrics and Gynecologists and Society for Maternal Fetal Medicine. (2017). Practice bulletin no. 163: screening for fetal aneuploidy. Obstetrics & Gynecology, 127, e123–e137.

Benn, P., & Chapman, A. R. (2016). Ethical and practical challenges in providing noninvasive prenatal testing for chromosome abnormalities: an update. Current Opinion in Obstetrics & Gynecology, 28, 119–124.

Benn, P., Borrell, A., Chiu, R. W., Cuckle, H., Dugoff, L., Faas, B., et al. (2015). Position statement from the chromosome abnormality screening committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal Diagnosis, 35, 725–734.CrossRef

Bernhardt, B. A., Kellom, K., Barbarese, A., Faucett, W. A., & Wapner, R. J. (2014). An exploration of genetic counselors’ needs and experiences with prenatal chromosomal microarray testing. Journal of Genetic Counseling, 23, 938–947.CrossRef

Bianchi, D. W., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Sehnert, A. J., Rava, R. P., & the MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. (2012). Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstetrics & Gynecology, 119, 890–901.CrossRef

Bianchi, D. W., Parker, R. L., Wentworth, J., Madankuma, R., Saffer, C., Das, A., for the CARE Study Group, et al. (2014). DNA sequencing versus standard prenatal aneuploidy screening. New England Journal of Medicine, 370, 799–808.CrossRef

Birks, M., Chapman, Y., & Francis, K. (2008). Memoing in qualitative research: probing data and processes. Journal of Research in Nursing, 13, 68–75.CrossRef

Brierley, K. L., Blouch, E., Cogswell, W., Homer, J. P., Pencarinha, D., Stanislaw, C. L., & Matloff, E. T. (2012). Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. The Cancer Journal, 18, 303–309.CrossRef

Brison, N., Van Den Bogaert, K., Dehaspe, L., Van den Oever, J. M., Janssens, K., Blaumeiser, B., Peeters, H., et al. (2017). Accuracy and clinical value of maternal incidental findings during noninvasive prenatal testing for fetal aneuploidies. Genetics in Medicine, 19, 306–313.CrossRef

Chandrasekharen, S., Minea, R M. A., Hung, A., & Allyse, M. (2014). Noninvasive prenatal testing goes global. Science Translational Medicine, 6, 231fs15.

Chapman, A. R., & Benn, P. A. (2013). Noninvasive prenatal testing for early sex identification. A few benefits and many concerns. Perspectives in Biology and Medicine, 56, 530–547.CrossRef

Chen, E. Z., Chiu, R. W., Sun, H., Akolekar, R., Chan, K. C., Leung, T. Y., et al. (2011). Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One, 6, e21791.CrossRef

Chitty, L. S., & Bianchi, D. W. (2013). Noninvasive prenatal testing: the paradigm is shifting rapidly. Prenatal Diagnosis, 33, 511–513.CrossRef

Cho, R. N., Plunkett, B. A., Wolf, M. S., Simon, C. E., & Grobman, W. A. (2007). Health literacy and patient understanding of screening tests for aneuploidy and neural tube defects. Prenatal Diagnosis, 27, 463–467.CrossRef

Cleary-Goldman, J., Morgan, M. A., Malone, F. D., Robinson, J. N., D’Alton, M. E., & Schulkin, J. (2006). Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists. Obstetrics & Gynecology, 107, 11–17.CrossRef

Corbin, J., & Strauss, A. (2008). Basics of qualitative research: techniques and procedures for developing grounded theory, 3rd ed. Thousand Oaks: Sage Publications.CrossRef

Devers, P. L., Cronister, A., Ormond, K. E., Facio, F., Brasington, C. K., & Flodman, P. (2013). Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. Journal of Genetic Counseling, 22, 291–295.CrossRef

Dharajiya, N. G., Grosu, D. S., Farkas, D. H., McCullough, R. M., Almasri, E., Sun, Y., Kim, S. K., et al. (2017). Incidental detection of maternal neoplasia in noninvasive prenatal testing. Clinical Chemistry, published online ahead of print.CrossRef

Dondorp, W., De Wert, G., Bombard, Y., Bianchi, D. W., Bergmann, C., Borry, P., Chitty, L. S., Fellmann, F., Forzano, F., Hall, A., & Henneman, L. (2015). Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. European Journal of Human Genetics, 23, 1438–1450.CrossRef

Edmonds, B. T., Krasny, S., Srinivas, S., & Shea, J. (2012). Obstetric decision-making and counseling at the limits of viability. American Journal of Obstetrics and Gynecology, 206, 248.e1–248.e5.CrossRef

Elwyn, G., Edwards, A., Mowle, S., Wensing, M., Wilkinson, C., Kinnersley, P., & Grol, R. (2001). Measuring the involvement of patients in shared decision-making: a systematic review of instruments. Patient Education and Counseling, 43, 5–22.CrossRef

Farrell, R. M., Mercer, M. B., Agatisa, P. K., Smith, M. B., & Philipson, E. (2014). It’s more than a blood test: patients’ perspectives on noninvasive prenatal testing. Journal of Clinical Medicine, 3, 614–631.CrossRef

Farrell, R. M., Agatisa, P. K., Mercer, M. B., Smith, M. B., & Philipson, E. (2015). Balancing risks: the core of women’s decisions about noninvasive prenatal testing. AJOB Empirical Bioethics, 6, 42–53.CrossRef

Giles, M. E., Murphy, L., Krstic, N., Sullivan, C., Hashmi, S. S., & Stevens, B. (2017). Prenatal cfDNA screening results indicative of maternal neoplasm: survey of current practice and management needs. Prenatal Diagnosis, 37, 126–132.CrossRef

Gregg, A. R., Gross, S. J., Best, R. G., Monaghan, K. G., Bajaj, K., & Skotko, B. G. (2013). ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genetics in Medicine, 15, 395–398.CrossRef

Gregg, A. R., Skotko, B. G., Benkendorf, J. L., Monaghan, K. G., Bajaj, K., Best, R. G., Klugman, S., & Watson, M. S. (2017). Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Obstetrical & Gynecological Survey, 72, 6–8.CrossRef

Guttmacher, A. E., Porteous, M. E., & McInerney, J. D. (2007). Educating health-care professionals about genetics and genomics. Nature Reviews Genetics, 8, 151–157.CrossRef

Harrington, K., Armstrong, V., Freeman, J., Aquilina, J., & Campbell, S. (1996). Fetal sexing by ultrasound in the second trimester: maternal preference and professional ability. Ultrasound in Obstetrics & Gynecology, 8, 318–321.CrossRef

Haymon, L., Simi, E., Moyer, K., Aufox, S., & Ouyang, D. W. (2014). Clinical implementation of noninvasive prenatal testing among maternal fetal medicine specialists. Prenatal Diagnosis, 34, 416–423.CrossRef

Horn, R., & Parker, M. (2017). Opening Pandora’s box? Ethical issues in prenatal whole genome and exome sequencing. Prenatal Diagnosis, 37, 1–6.CrossRef

Horsting, J. M., Dlouhy, S. R., Hanson, K., Quaid, K., Bai, S., & Hines, K. A. (2014). Genetic counselors’ experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy. Journal of Genetic Counseling, 23, 377–400.CrossRef

Hurle, B., Citrin, T., Jenkins, J. F., Kaphingst, K. A., Lamb, N., Roseman, J. E., & Bonham, V. L. (2013). What does it mean to be genomically literate? National Human Genome Research Institute meeting report. Genetics in Medicine, 15, 658–663.CrossRef

Johnston, J., Farrell, R. M., & Parens, E. (2017). Supporting women’s autonomy in prenatal testing. New England Journal of Medicine, 377, 505–507.CrossRef

Kalynchuk, E. J., Althouse, A., Parker, L. S., Saller, D. N., & Rajkovic, A. (2015). Prenatal whole-exome sequencing: parental attitudes. Prenatal Diagnosis, 35, 1030–1036.CrossRef

Kubendran, S., Sivamurthy, S., & Schaefer, G. B. (2017). A novel approach in pediatric telegenetic services: geneticist, pediatrician and genetic counselor team. Genetics in Medicine, advance online publication.CrossRef

Légaré, F., Guerrier, M., Nadeau, C., Rhéaume, C., Turcotte, S., & Labrecque, M. (2013). Impact of DECISION+ 2 on patient and physician assessment of shared decision making implementation in the context of antibiotics use for acute respiratory infections. Implementation Science, 8, 144.CrossRef

Lewis, C., Hill, M., & Chitty, L. S. (2017). Offering non-invasive prenatal testing as part of routine clinical service. Can high levels of informed choice be maintained? Prenatal Diagnosis, 1–8.

Makoul, G., & Clayman, M. L. (2006). An integrative model of shared decision making in medical encounters. Patient Education and Counseling, 60, 301–312.CrossRef

Mennuti, M. T., Chandrasekaran, S., Khalek, N., & Dugof, L. (2015). Cell-free DNA screening and sex chromosome aneuploidies. Prenatal Diagnosis, 35, 980–985.CrossRef

Mozersky, J., & Mennuti, M. T. (2012). Cell-free fetal DNA testing: who is driving implementation? Genetics in Medicine, 15, 433–434.CrossRef

Newson, A. J. (2008). Ethical aspects arising from non-invasive fetal diagnosis. Seminars in Fetal and Neonatal Medicine, 13(2), 103–108 WB Saunders.CrossRef

Nicolaides, K. H., Wright, D., Poon, L. C., Syngelaki, A., & Gil, M. D. M. (2013). First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound in Obstetrics & Gynecology, 42, 41–50.CrossRef

Norton, M. E., Brar, H., Weiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., Rodriguez, M. H., Williams III, J., Mitchell, M. E., Adair, C. D., Lee, H., Jacobsson, B., Tomlinson, M. W., Oepkes, D., Hollemon, D., Sparks, A. B., Oliphant, A., & Song, K. (2012). Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. American Journal of Obstetrics & Gynecology, 207, 137.e1.CrossRef

NVivo qualitative data analysis software. (2008). QSR International Pty Ltd. Version 8.

Oepkes, D., Yaron, Y., Kozlowski, P., Rego de Sousa, M. J., Bartha, J. L., van den Akker, E. S., Dornan, S. M., Krampl-Bettelheim, E., Schmid, M., Wielgos, M., Cirigliano, V., di Renzo, G. C., Cameron, A., Calda, P., & Tabor, A. (2014). Counseling for non-invasive prenatal testing (NIPT): what pregnant women may want to know. Ultrasound in Obstetrics & Gynecology, 44, 1–5.CrossRef

Pain, E. (2016). Genetic counseling: a growing area of opportunity. Science. Accessed online: http://www.sciencemag.org/careers/2016/06/genetic-counseling-growing-area-opportunity.

Palomaki, G. E., Kloza, E. M., O’Brien, B. M., Eklund, E. E., & Lambert-Messerlian, G. M. (2017). The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population. Genetics in Medicine, 19, 778–786.CrossRef

Parham, L., Michie, M., & Allyse, M. (2017). Expanding use of cfDNA screening in pregnancy: current and emerging ethical, legal and social issues. Current Genetic Medicine Reports, 5, 44–53.CrossRef

Pergament, E., Cuckle, H., Zimmermann, B., Banjevic, M., Sigurjonsson, S., Ryan, A., Hall, M. P., Dodd, M., Lacroute, P., Stosic, M., Chopra, N., Hunkapiller, N., Prosen, D. E., McAdoo, S., Demko, Z., Siddiqui, A., Hill, M., & Rabinowitz, M. (2014). Single-nucleotide polymorphism–based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstetrics & Gynecology, 124, 210–221.CrossRef

Plon, S. E., Cooper, H. P., Parks, B., Dhar, S., Kelly, P. A., Weinberg, A. D., et al. (2011). Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genetics in Medicine, 13, 148–154.CrossRef

Ryan, G., & Bernard, H. (2003). Techniques to identify themes. Field Methods, 15, 85–109.CrossRef

Sachs, A., Blanchard, L., Buchanan, A., Norwitz, E., & Bianchi, D. W. (2015). Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. Prenatal Diagnosis, 35, 968–971.CrossRef

Sayres, L. C., Allyse, M., Norton, M. E., & Cho, M. K. (2011). Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenatal Diagnosis, 31, 1070–1076.CrossRef

Seavilleklein, V. (2009). Challenging the rhetoric of choice in prenatal screening. Bioethics, 23, 68–77.CrossRef

Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Resting and Molecular Biomarkers, 17, 219–225.CrossRef

Suskin, E., Hercher, L., Aaron, K. E., & Bajaj, K. (2016). The integration of noninvasive prenatal screening into the existing prenatal paradigm: a survey of current genetic counseling practice. Journal of Genetic Counseling, 25, 1032–1043.CrossRef

Wapner, R. J., Babiarz, J. E., Levy, B., Stosic, M., Zimmermann, B., Sigurjonsson, S., et al. (2015). Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. American Journal of Obstetrics & Gynecology, 212, 332–3e1.CrossRef

Xi, Y., Arbabi, A., McNaughton, A. J. M., Hamilton, A., Hull, D., Perras, H., Chiu, T., et al. (2017). Noninvasive prenatal detection of trisomy 21 by targeted semiconductor sequencing: a technical feasibility study. Fetal diagnosis and therapy, advance online publication.

Zhang, H., Gao, Y., Jiang, F., Fu, M., Yuan, Y., Guo, Y., Zhu, Z., Lin, M., Liu, Q., Tian, Z., Zhang, H., Chen, F., Lau, T. K., Zhao, L., Yi, X., Yin, Y., & Wang, W. (2015). Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstetrics & Gynecology, 45, 530–538.CrossRef

Title: Genetic Counselors’ Perspectives About Cell-Free DNA: Experiences, Challenges, and Expectations for Obstetricians
Authors: Patricia K. Agatisa
Mary Beth Mercer
Marissa Coleridge
Ruth M. Farrell
Publication date: 01-12-2018
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 6/2018
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-018-0268-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic Counselors’ Perspectives About Cell-Free DNA: Experiences, Challenges, and Expectations for Obstetricians

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals

Issue Highlights

The Relationship Between the Supervisory Working Alliance and Student Self-Efficacy in Genetic Counseling Training

Disability Experiences and Perspectives Regarding Reproductive Decisions, Parenting, and the Utility of Genetic Services: a Qualitative Study

Adopted Individuals’ Views on the Utility and Value of Expanded Carrier Screening

Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience